Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -107.08% is 92% below its 5-year average of -55.83%, around the middle of its 5-year range (-299.37%–-19.32%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.95% above its 12-month average of -115.08%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -107.08%.
RETURN ON INVESTED CAPITAL (ROIC)
-107.08%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-115.08%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-43.89%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-55.83%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.95%
CURRENT VS 3Y AVG
-144.00%
CURRENT VS 5Y AVG
-91.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-200.42%
vs the sector median at left
Quince Therapeutics, Inc.
Market Cap
$7.64M
Return on Invested Capital (ROIC)
-107.08%
TTM Avg
-115.08%
3Y Avg
-43.89%
5Y Avg
-55.83%
Market Cap
$7.75M
Return on Invested Capital (ROIC)
-92.94%
TTM Avg
-279.36%
3Y Avg
-244.50%
5Y Avg
-201.18%
Market Cap
$7.53M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-166.69%
3Y Avg
-591.28%
5Y Avg
-439.14%
Market Cap
$7.86M
Return on Invested Capital (ROIC)
-33.73%
TTM Avg
-84.97%
3Y Avg
-168.83%
5Y Avg
-136.52%
Market Cap
$7.86M
Return on Invested Capital (ROIC)
-92.93%
TTM Avg
-227.52%
3Y Avg
-201.78%
5Y Avg
-175.64%
Market Cap
$7.93M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-259.12%
3Y Avg
-153.58%
5Y Avg
-167.70%
Market Cap
$7.32M
Return on Invested Capital (ROIC)
-995.44%
TTM Avg
-481.38%
3Y Avg
-268.85%
5Y Avg
-219.77%
Market Cap
$8.07M
Return on Invested Capital (ROIC)
-457.75%
TTM Avg
-214.65%
3Y Avg
-192.14%
5Y Avg
-209.63%
Market Cap
$7.21M
Return on Invested Capital (ROIC)
-211.58%
TTM Avg
-206.45%
3Y Avg
-187.44%
5Y Avg
-143.49%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.64M | -107.08% | -115.08% | -43.89% | -55.83% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | -92.94% | -279.36% | -244.50% | -201.18% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.53M | N/A | -166.69% | -591.28% | -439.14% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.86M | -33.73% | -84.97% | -168.83% | -136.52% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.86M | -92.93% | -227.52% | -201.78% | -175.64% |
| Traws Pharma, Inc. (TRAW)vs › | $7.93M | N/A | -259.12% | -153.58% | -167.70% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.32M | -995.44% | -481.38% | -268.85% | -219.77% |
| GT Biopharma, Inc. (GTBP)vs › | $8.07M | -457.75% | -214.65% | -192.14% | -209.63% |
| Longeveron Inc. (LGVN)vs › | $7.21M | -211.58% | -206.45% | -187.44% | -143.49% |
| HeartSciences Inc. (HSCS)vs › | $8.10M | N/A | -174.21% | -638.36% | -516.05% |
ROIC
-107.1%
ROE
-85.2%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -107.08% |
| 2026-03-31 | -299.37% |
| 2025-12-31 | -84.21% |
| 2025-09-30 | -47.64% |
| 2025-06-30 | -37.11% |
| 2025-03-31 | -59.78% |
| 2024-12-31 | -51.66% |
| 2024-09-30 | -44.28% |
| 2024-06-30 | -43.25% |
| 2024-03-31 | -20.90% |
| 2023-12-31 | -19.32% |
| 2023-09-30 | -37.23% |
| 2023-06-30 | -37.38% |
| 2023-03-31 | -47.84% |
| 2022-12-31 | -51.63% |
| 2022-09-30 | -66.09% |
| 2022-06-30 | -74.47% |
| 2022-03-31 | -83.51% |
| 2021-12-31 | -75.89% |
| 2021-09-30 | -65.75% |
| 2021-06-30 | -61.50% |
| 2021-03-31 | -53.84% |
| 2020-12-31 | -45.74% |
| 2020-09-30 | -37.71% |
| 2020-06-30 | -29.02% |
| 2020-03-31 | -23.36% |
| 2019-12-31 | -33.92% |
| 2019-09-30 | -23.62% |
| 2019-06-30 | -16.42% |
| 2019-03-31 | -23.18% |
| 2018-12-31 | -16.97% |
